HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG(TM) Device

Stock Information for HeartSciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About HeartSciences Inc.

HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
HeartSciences Announces Conference Participation and Investor Webinar
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.